The American Association of Clinical Endocrinology (AACE) and European Society of Cardiology in collaboration with the European Association for the Study of Diabetes (ESC/EASD) both updated their treatment algorithms in 2019 to recommend the use of GLP-1 RA and SGLT-2i as alternate therapy options to metformin based on cardiovascular (CV) and renal comorbidities independent of glycemic control [4, 5]. This evidence concerns the gene GLP1R and diabetes mellitus.